175 related articles for article (PubMed ID: 12443714)
1. Differential heparanase-1 expression in malignant and benign pheochromocytomas.
Quiros RM; Kim AW; Maxhimer J; Gattuso P; Xu X; Prinz RA
J Surg Res; 2002 Nov; 108(1):44-50. PubMed ID: 12443714
[TBL] [Abstract][Full Text] [Related]
2. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
3. Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.
Zhu Y; He HC; Yuan F; Zhang J; Rui WB; Zhao JP; Shen ZJ; Ning G
Endocrine; 2010 Aug; 38(1):93-9. PubMed ID: 20960108
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
Salmenkivi K; Haglund C; Ristimäki A; Arola J; Heikkilä P
J Clin Endocrinol Metab; 2001 Nov; 86(11):5615-9. PubMed ID: 11701743
[TBL] [Abstract][Full Text] [Related]
5. [Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].
Jiang CX; Zeng Z; Wang T; Liu X; Liu R; Li Y
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):762-6. PubMed ID: 22336161
[TBL] [Abstract][Full Text] [Related]
6. Survivin: a novel neuroendocrine marker for pheochromocytoma.
Koch CA; Vortmeyer AO; Diallo R; Poremba C; Giordano TJ; Sanders D; Bornstein SR; Chrousos GP; Pacak K
Eur J Endocrinol; 2002 Mar; 146(3):381-8. PubMed ID: 11888845
[TBL] [Abstract][Full Text] [Related]
7. Pheochromocytomas: can malignant potential be predicted?
John H; Ziegler WH; Hauri D; Jaeger P
Urology; 1999 Apr; 53(4):679-83. PubMed ID: 10197840
[TBL] [Abstract][Full Text] [Related]
8. Remarkably suppressed manganese superoxide dismutase activity in malignant pheochromocytoma.
Nakada T; Kubota Y; Sasagawa I; Yagisawa T; Watanabe M; Ishigooka M
J Urol; 1995 Jun; 153(6):1787-90. PubMed ID: 7752317
[TBL] [Abstract][Full Text] [Related]
9. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
10. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience over 48 years with pheochromocytoma.
Goldstein RE; O'Neill JA; Holcomb GW; Morgan WM; Neblett WW; Oates JA; Brown N; Nadeau J; Smith B; Page DL; Abumrad NN; Scott HW
Ann Surg; 1999 Jun; 229(6):755-64; discussion 764-6. PubMed ID: 10363888
[TBL] [Abstract][Full Text] [Related]
12. Heparanase expression correlates with malignant potential in human colon cancer.
Nobuhisa T; Naomoto Y; Ohkawa T; Takaoka M; Ono R; Murata T; Gunduz M; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tsujigiwa H; Nagatsuka H; Nakajima M; Tanaka N
J Cancer Res Clin Oncol; 2005 Apr; 131(4):229-37. PubMed ID: 15625607
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic role of inhibin α-subunit and inhibin/activin β-subunit in adrenal cortical and medullary tumors in Egyptian patients.
Elmoneim HM; Samaka RM; Ali H
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):462-9. PubMed ID: 22417854
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of telomerase activity in malignant pheochromocytoma.
Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
[TBL] [Abstract][Full Text] [Related]
15. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.
Xu X; Quiros RM; Maxhimer JB; Jiang P; Marcinek R; Ain KB; Platt JL; Shen J; Gattuso P; Prinz RA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5968-79. PubMed ID: 14676122
[TBL] [Abstract][Full Text] [Related]
16. Stathmin as a marker for malignancy in pheochromocytomas.
Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
[TBL] [Abstract][Full Text] [Related]
17. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
Patterson E; Webb R; Weisbrod A; Bian B; He M; Zhang L; Holloway AK; Krishna R; Nilubol N; Pacak K; Kebebew E
Endocr Relat Cancer; 2012 Apr; 19(2):157-66. PubMed ID: 22241719
[TBL] [Abstract][Full Text] [Related]
18. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
Helman LJ; Cohen PS; Averbuch SD; Cooper MJ; Keiser HR; Israel MA
J Clin Oncol; 1989 Nov; 7(11):1720-5. PubMed ID: 2809684
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.
Luo Z; Li J; Qin Y; Ma Y; Liang X; Xian J; Lu D; Wei M; Yang JY; Yang MQ; He Z
Endocr Pathol; 2006; 17(4):387-98. PubMed ID: 17525487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
